Message from the Program Chair of the 2007 Annual Scientific Meeting

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

A user successfully halted hair loss using finasteride for 17 years and recently switched to dutasteride for stronger DHT suppression. They experienced no major side effects, maintained a full head of hair, and fathered three children without issues.

Dutasteride potentially being more effective than Finasteride in treating hair loss due to its ability to suppress DHT levels more significantly. Dutasteride also has fewer sexual side effects compared to Finasteride.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.